Tags

Type your tag names separated by a space and hit enter

Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus.
Head Neck. 2019 09; 41(9):2873-2882.HN

Abstract

BACKGROUND

This study was designed to assess the therapeutic effect of urokinase-targeted recombinant oncolytic Sendai virus, termed "BioKnife," on anaplastic thyroid carcinoma (ATC).

METHODS

Urokinase activity was investigated in human ATC cell lines, and BioKnife cytotoxicity against the cell lines was evaluated in vitro. Orthotopic mouse models of ATC were treated with three intratumoral injections of BioKnife, control virus, or phosphate-buffered saline (PBS) and were observed daily until >20% weight loss occurred.

RESULTS

All three ATC cell lines showed a high level of urokinase activity. BioKnife induced urokinase-dependent cell fusion and cytotoxicity in all cell lines. Orthotopic models treated with BioKnife showed significantly prolonged survival compared with models treated with control virus or PBS (BioKnife 41.6 ± 15.0, control virus 17.0 ± 2.9, PBS 17.7 ± 6.3 days).

CONCLUSIONS

BioKnife exerted therapeutic effects in orthotopic ATC mouse models. Thus, BioKnife represents a possible treatment option for ATC.

Authors+Show Affiliations

Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.Department of Otolaryngology - Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan.Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.Section of Gene Medicine, R&D Center, ID Pharma Co., Ltd., Tokyo, Japan.R&D Laboratory for Innovative Biotherapeutics Science, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.Department of Surgery, Toho University School of Medicine, Tokyo, Japan.Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30969451

Citation

Miyagawa, Yoshihiro, et al. "Induction of Cell Fusion/apoptosis in Anaplastic Thyroid Carcinoma in Orthotopic Mouse Model By Urokinase-specific Oncolytic Sendai Virus." Head & Neck, vol. 41, no. 9, 2019, pp. 2873-2882.
Miyagawa Y, Araki K, Yamashita T, et al. Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus. Head Neck. 2019;41(9):2873-2882.
Miyagawa, Y., Araki, K., Yamashita, T., Tanaka, S., Tanaka, Y., Tomifuji, M., Ueda, Y., Yonemitsu, Y., Shimada, H., & Shiotani, A. (2019). Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus. Head & Neck, 41(9), 2873-2882. https://doi.org/10.1002/hed.25769
Miyagawa Y, et al. Induction of Cell Fusion/apoptosis in Anaplastic Thyroid Carcinoma in Orthotopic Mouse Model By Urokinase-specific Oncolytic Sendai Virus. Head Neck. 2019;41(9):2873-2882. PubMed PMID: 30969451.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus. AU - Miyagawa,Yoshihiro, AU - Araki,Koji, AU - Yamashita,Taku, AU - Tanaka,Shingo, AU - Tanaka,Yuya, AU - Tomifuji,Masayuki, AU - Ueda,Yasuji, AU - Yonemitsu,Yoshikazu, AU - Shimada,Hideaki, AU - Shiotani,Akihiro, Y1 - 2019/04/10/ PY - 2018/03/28/received PY - 2019/03/19/revised PY - 2019/03/25/accepted PY - 2019/4/11/pubmed PY - 2019/4/11/medline PY - 2019/4/11/entrez KW - Sendai virus KW - anaplastic thyroid carcinoma KW - oncolytic virus KW - urokinase-type plasminogen activator KW - virotherapy SP - 2873 EP - 2882 JF - Head & neck JO - Head Neck VL - 41 IS - 9 N2 - BACKGROUND: This study was designed to assess the therapeutic effect of urokinase-targeted recombinant oncolytic Sendai virus, termed "BioKnife," on anaplastic thyroid carcinoma (ATC). METHODS: Urokinase activity was investigated in human ATC cell lines, and BioKnife cytotoxicity against the cell lines was evaluated in vitro. Orthotopic mouse models of ATC were treated with three intratumoral injections of BioKnife, control virus, or phosphate-buffered saline (PBS) and were observed daily until >20% weight loss occurred. RESULTS: All three ATC cell lines showed a high level of urokinase activity. BioKnife induced urokinase-dependent cell fusion and cytotoxicity in all cell lines. Orthotopic models treated with BioKnife showed significantly prolonged survival compared with models treated with control virus or PBS (BioKnife 41.6 ± 15.0, control virus 17.0 ± 2.9, PBS 17.7 ± 6.3 days). CONCLUSIONS: BioKnife exerted therapeutic effects in orthotopic ATC mouse models. Thus, BioKnife represents a possible treatment option for ATC. SN - 1097-0347 UR - https://www.unboundmedicine.com/medline/citation/30969451/Induction_of_cell_fusion/apoptosis_in_anaplastic_thyroid_carcinoma_in_orthotopic_mouse_model_by_urokinase_specific_oncolytic_Sendai_virus_ L2 - https://doi.org/10.1002/hed.25769 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.